By continuing to use our service, you agree to our use of cookies. stock news by MarketWatch. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. Theratechnologies Inc. We also use them to share usage. 49%) At close: 04:00PM EST 1. S. stock news by MarketWatch. Theratechnologies Inc. If you have JavaScript enabled then this page should refresh automatically, if it does not then please tap the button below. A live webcast of Dr. Senior Director, Communications & Corporate Affairs. MONTREAL, Feb. Their average twelve-month price target is $36. We currently market prescription products for people with HIV in the United States. Register for your free account today at data. Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, Feb. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. Gary Littlejohn Stockhouse. Further information about Theratechnologies is available on the Company's website at on SEDAR at and on EDGAR at MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Statut du système de négociation. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies was founded in 1993 and is headquartered in Montreal, Canada. 1-514-336-7800. Visit the TSX ETF Investor Centre to access our screener and comparison tool. . P. (2021-12-06 | TSX:TH) Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV. By continuing to use our service, you agree to our use of cookies. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. (NASDAQ:NASDAQ:THTX) Q1 2021 Earnings Conference Call April 14, 2021 8:30 AM ETCompany ParticipantsDenis Boucher - Vice President,. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. We currently market prescription products for people with. By continuing to use our service, you agree to our use of cookies. Phone Number (514) 336-7800. Last Reviewed: February 24, 2023. com. 54% and a negative trailing twelve-month return on equity of. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Stockhouse. com 10/16/2023. com. T. 5000 0. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. By continuing to use our. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2019-08-07 | TSX:TH) Jean-Denis Talon Retires From Theratechnologies' Board of Directors. (“Theratechnologies”) with the Securities and Exchange Commission (the. FDA for its IV push form of administration of Trogarzo. The abstract and poster can be found on Theratechnologies’ website. Theratechnologies Inc. com uses cookies on this site. Agreement in principle on key amendments to loan. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. 35 as of 10:41 a. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. Track Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. T. Northwest also announces an update on its. : Nasdaq Theratechnologies Inc. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. We also use them to share usage information with our partners. View real-time stock prices and stock quotes for a full financial overview. MONTREAL, Sept. 38. CALGARY, AB, May 12, 2022 /PRNewswire/ - Exro Technologies Inc. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Aug. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. FY2022 revenue. Cookies are used to. Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. 9 million as at August 31, 2023. (TH. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an. 57%) Q1 2020 Earnings Call. com uses cookies on this site. Theratechnologies Announces 1-for-4 Reverse Stock Split. THTX | Complete Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (for. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. Stockhouse. MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 74M. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (Theratechnologies, or the Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal year 2022. com. Sol-Gel Technologies (NASDAQ:SLGL) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk,. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. We also use them to share usage information with our partners. 5%. was a. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. com uses cookies on this site. 20% from a day low at $1. Theratechnologies (TSX: TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. The business had revenue of $27. 65 per cent to C$1. 2% to $21. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. 1300 (+9. 25. 23 to a day high of $1. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. stock price gained 1. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and optimize the protocol of its Phase 1 oncology. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of. Small cap stock market news and analysis, portfolio tracking, investor message boards and forums (bullboards), newsletter aggregation and detailed snapshots of stock quotes for. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. Stockhouse. This enduring webinar with Drs Arsalan Shah, Sarah Rowan, Stacey Trooskin, and Juliana Wallace will provide critical updates on specific strategies to improve testing and linkage to care, retention in care, and an overview of guidelines for treatment of HIV and HCV. Theratechnologies, Inc. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. 00. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. is a pharmaceutical company. Further. com uses cookies on this site. 82 million. -4. Marsolais’ presentation will be available through. Proceeds to Be Used to Redeem All of the Outstanding 5. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on EDGAR at . Phone Number 15143319691. By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. com uses cookies on this site. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. . Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. , Senior Vice President and Chief Medical Officer, Theratechnologies commented, “The exciting new data in triple negative breast and ovarian cancer demonstrate. Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City. MONTREAL, Dec. Clinical-stage pharmaceutical company Theralase Technologies Inc. MONTREAL, Oct. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut. 49) by $0. Shares of Theratechnologies are up 4. stock news by MarketWatch. MONTREAL, Nov. com uses cookies on this site. com uses cookies on this site. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. (THTX) stock. GlobeNewswire. 1-438. - Cash, bonds and money market funds of US$22. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Inc. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. Free cash flow. Theratechnologies présente des données démontrant la surexpression de la sortiline (SORT1) dans plusieurs types de tumeurs au 34e symposium de l’EORTC-NCI-AACRVice President, Communications and Corporate Affairs. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. 3 brokerages have issued 1-year price objectives for Theratechnologies' shares. By continuing to use our service, you agree to our use of cookies. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 35 as of 10:41 a. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. Cookies are used to offer you a better browsing experience and to analyze our traffic. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug. Biopharma Theratechnologies (NASDAQ:THTX) Friday announced that a study evaluating an intramuscular (IM) method of administration for its therapy, Trogarzo, did not meet the primary endpoint. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon;. FAQ – Émetteurs inscrits NOUVEAU. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. The Company currently commercializes two products in the field of HIV. TH | May 19, 2023. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. About Theratechnologies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. 86%. TO) on CEO. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xToronto, Ontario-- (Newsfile Corp. : Renegotiated Lease to Generate Substantial Annual Savings. - On track to meet FY2022. With the company starting 2023 with 8,725 employees, that’s an 11. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. 40%. 71. 08). By continuing to use our service, you agree to our use of cookies. Further information about Theratechnologies is available on the Company’s website at on SEDAR+ at and. 17% from a day low at $1. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. First Quarter Fiscal 2022 Financial Results. Theratechnologies Provides Details About R&D Day Webcast. Theratechnologies Stock (NASDAQ: THTX) stock price, news, charts, stock research, profile. On average, they expect the company's stock price to reach $36. 4% from the stock's current price. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. MONTREAL, Aug. com. 68 to a day high of $1. Cookies are used to offer you a better browsing experience and to analyze our traffic. Microsoft to invest $500M in Quebec AI economy. B2Gold Declares Fourth Quarter 2023 Dividend. The price has fallen in 7 of the last 10 days and is down by -30. Montréal, Québec, Canada . By continuing to use our service, you agree to our use of cookies. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April. Stockhouse. TORONTO, May 19, 2023 /CNW/ - This press release is being disseminated as required by. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. MONTREAL, Oct. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. Consensus forecasts updated Jul 21. 00 in the next twelve months. has received a $100 million binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management. TH | February 28, 2023. By continuing to use our service, you agree to our use of cookies. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. 75. - October 10, 2023) - KO Gold Inc. We also use them to share. com uses cookies on this site. com uses cookies on this site. Theratechnologies layoffs. Stockhouse. 2 million. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. 51 S1. TH | September 5, 2023. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. 86 million for the quarter. - Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. (2015-07-23 | TSX:TH) Theratechnologies Announces $9,600,000 Firm Offering of Units and Filing of Preliminary Short Form Prospectus. (NASDAQ:NASDAQ:THTX) Q3 2022 Earnings Conference Call October 13, 2022 8:30 AM ETCompany ParticipantsElif McDonald - Head of Investor RelationsPaul Levesque -. -based clinical sites participating in the conduct of the Phase. Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. 23) diluted earnings per. Theratechnologies Inc. Theratechnologies Inc. Investor Relations. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. European Headquarters. We also use them to share usage. We also use them to share usage information with our partners. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. Cookies are used to offer you a better browsing experience and to analyze our traffic. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal. According to 3 analysts, the average rating for THTX stock is "Buy. Theratechnologies reduces R&D head count to compensate for sales setback. THERATECHNOLOGIES INC. Message Board Total Posts: 4. Cookies are used to offer you a better browsing experience and to analyze our traffic. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. (TSX: TH, Forum) has long been a favourite among Healthcare Bullboard posters who have been following its developments to commercialize innovative therapies. Once expert advice is considered, the Company. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. During the last trading day the stock fluctuated 4. TH | October 13, 2022. Theratechnologies Inc. 514-336-7800. Investor Relations. TH1902 combines Theratechnologies’ proprietary peptide to. 63. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. T. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. . " The 12-month stock price forecast is $18. Paul Levesque - President. 2% for this period. FAQ – Utilisateurs de TMX Argent NOUVEAU. com uses cookies on this site. This news release constitutes a “designated news release” for the purposes of the Company’s. Common Shares (THTX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00. Stockhouse. , alpha and beta) for all equities such as Theratechnologies. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement. View real-time stock prices and stock quotes for a full financial overview. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound. Browse posts by Sector and Subsector. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. com uses cookies on this site. . : Renegotiated Lease to Generate Substantial Annual Savings Stockhouse. The business had revenue of $27. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Cookies are used to offer you a better browsing experience and to analyze our traffic. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. 9 million, adjusted EBITDA of $2. S. We also use them to share usage information with our partners. Cookies are used to offer you a better browsing experience and to analyze our traffic. RESSOURCES. 60%. Further. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. 2% per year. m. ET. By continuing to use our service, you agree to our use of cookies. Read More. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. Presented in part at the XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada (abstracts TUP30058 AND THLB0218). ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to. Company Type For Profit. This suggests a possible upside of 2,471. Theratechnologies Inc. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. Theratechnologies inc. com. TH1902, the leading product candidate derived from the SORT1+ Technology, is a first-in-class peptide-drug. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. stock news by MarketWatch. NCU. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. We also use them to share usage. By continuing to use our service, you agree to our use of cookies. If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or. MONTREAL, Feb. (CSE: KOG) (" KO Gold " or the " Company ") is pleased to announce that the common shares of the Company will commence trading on the Canadian Securities Exchange (CSE) effective at the open of business on Wednesday, October 11, 2023, under the symbol " KOG ". com uses cookies on this site. Theratechnologies inc. US Headquarters. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to shareholders. Follow. View real-time stock prices and stock quotes for a full financial overview. 1-438. This news release constitutes a “designated news release” for the purposes. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third.